Table 2 Hazard ratios for specific breast cancer outcomes by BMI groups in patients with chemotherapy or hormonal plus chemotherapy (N=1049)
Outcome | Follow-up period | BMI (kg/m2) | No of events | Crude HR (95% CI) | Adjusted HR (95% CI) |
|---|---|---|---|---|---|
Breast cancer specific death | 0-10 yrs | <21 (N=81) | 43 | 1.70 (0.99, 2.91) | 1.13 (0.60, 2.14) |
21-24 (N=250) | 88 | 1.00 | 1.00 | ||
25-29 (N=349) | 107 | 0.99 (0.66, 1.47) | 0.96 (0.61, 1.51) | ||
30-34 (N=225) | 67 | 1.24 (0.82, 1.88) | 0.98 (0.62, 1.54) | ||
35+ (N=144) | 49 | 1.31 (0.81, 2.12) | 0.99 (0.57, 1.71) | ||
Whole study period | <21 | 44 | 1.66 (0.97, 2.84) | 1.11 (0.59, 2.09) | |
21-24 | 91 | 1.00 | 1.00 | ||
25-29 | 110 | 0.98 (0.66, 1.46) | 0.95 (0.61, 1.50) | ||
30-34 | 67 | 1.21 (0.80, 1.83) | 0.96 (0.62, 1.50) | ||
35+ | 49 | 1.28 (0.79, 2.07) | 0.96 (0.56, 1.67) | ||
Overall mortality | 0-10 yrs | <21 | 67 | 1.64 (0.98, 2.73) | 1.12 (0.61, 2.05) |
21-24 | 122 | 1.00 | 1.00 | ||
25-29 | 153 | 1.01 (0.69, 1.46) | 0.92 (0.60, 1.41) | ||
30-34 | 93 | 1.17 (0.79, 1.73) | 0.88 (0.57, 1.34) | ||
35+ | 65 | 1.37 (0.88, 2.16) | 1.05 (0.64, 1.73) | ||
Whole study period | <21 | 70 | 1.49 (0.89, 2.51) | 1.04 (0.57, 1.90) | |
21-24 | 130 | 1.00 | 1.00 | ||
25-29 | 163 | 0.97 (0.68, 1.40) | 0.87 (0.57, 1.32) | ||
30-34 | 100 | 1.18 (0.81, 1.72) | 0.89 (0.59, 1.33) | ||
35+ | 69 | 1.36 (0.87, 2.10) | 1.03 (0.63, 1.67) | ||
Death from other/unknown causes | 0-10 | <21 | 24 | 1.08 (0.22, 5.34) | 1.44 (0.21, 9.97) |
21-24 | 34 | 1.00 | 1.00 | ||
25-29 | 46 | 1.15 (0.41, 3.25) | 1.11 (0.33, 3.72) | ||
30-34 | 26 | 0.74 (0.21, 2.58) | 0.74 (0.21, 2.67) | ||
35+ | 16 | 1.64 (0.50, 5.43) | 1.55 (0.34, 7.18) | ||
Whole study period | <21 | 26 | 0.70 (0.14, 3.45) | 1.01 (0.19, 5.45) | |
21-24 | 39 | 1.00 | 1.00 | ||
25-29 | 53 | 0.98 (0.39, 2.43) | 0.78 (0.27, 2.29) | ||
30-34 | 33 | 1.04 (0.40, 2.72) | 1.15 (0.42, 3.11) | ||
35+ | 20 | 1.56 (0.54, 4.51) | 1.42 (0.40, 5.01) | ||
Loco-regional recurrence | 0-5 | <21 (N=81) | 13 | 1.04 (0.22, 4.98) | 1.24 (0.20, 7.64) |
21-24 (N=250) | 22 | 1.00 | 1.00 | ||
25-29 (N=349) | 23 | 0.87 (0.32, 2.40) | 1.13 (0.34, 3.73) | ||
30-34 (N=225) | 27 | 0.88 (0.28, 2.77) | 1.38 (0.36, 5.29) | ||
35+ (N=144) | 11 | 0.60 (0.12, 2.87) | 1.12 (0.16, 7.84) | ||
Whole study period | <21 | 17 | 1.58 (0.42, 6.02) | 2.08 (0.42, 10.23) | |
21-24 | 25 | 1.00 | 1.00 | ||
25-29 | 25 | 1.11 (0.42, 2.93) | 1.26 (0.41, 3.87) | ||
30-34 | 28 | 1.10 (0.37, 3.28) | 1.58 (0.44, 5.63) | ||
35+ | 12 | 0.63 (0.13, 3.04) | 1.17 (0.19, 7.21) | ||
Distant metastasis | 0-5 | <21 | 43 | 1.74 (0.66, 4.54) | 1.44 (0.51, 4.03) |
21-24 | 90 | 1.00 | 1.00 | ||
25-29 | 103 | 1.13 (0.57, 2.24) | 0.89 (0.44, 1.80) | ||
30-34 | 65 | 1.20 (0.56, 2.55) | 1.17 (0.51, 2.67) | ||
35+ | 62 | 1.62 (0.72, 3.64) | 1.69 (0.69, 4.11) | ||
Whole study period | <21 | 46 | 1.62 (0.67, 3.93) | 1.32 (0.52, 3.37) | |
21-24 | 103 | 1.00 | 1.00 | ||
25-29 | 127 | 1.38 (0.76, 2.53) | 1.05 (0.56, 1.94) | ||
30-34 | 87 | 1.50 (0.77, 2.90) | 1.23 (0.61, 2.49) | ||
35+ | 70 | 1.73 (0.82, 3.63) | 1.33 (0.61, 2.91) |